Literature DB >> 11283812

Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons.

R A Hajjeh1, P G Pappas, H Henderson, D Lancaster, D M Bamberger, K J Skahan, M A Phelan, G Cloud, M Holloway, C A Kauffman, L J Wheat.   

Abstract

We conducted a multicenter case-control study to identify risk factors for histoplasmosis among persons with acquired immunodeficiency syndrome (AIDS) and to evaluate predictors of a poor outcome (defined as death or admission to the intensive care unit). Patients with histoplasmosis were each matched by age, sex, and CD4 lymphocyte count to 3 controls. From 1996 through 1999, 92 case patients and 252 controls were enrolled. Of the case patients, 81 (89%) were men, 50 (55%) were black, 78 (85%) had a CD4 lymphocyte count of <100 cells/microL, 80 (87%) were hospitalized, and 11 (12%) died. Multivariable analysis found that receipt of antiretroviral therapy and of triazole drugs were independently associated with a decreased risk of histoplasmosis. Chronic medical conditions and a history of infections with herpes simplex virus were associated with poor outcome. Triazoles should be considered for chemoprophylaxis for persons with AIDS, especially those who take part in high-risk activities that involve frequent exposure to soil, who have CD4 lymphocyte counts of <100 cells/microL, and who live in areas where histoplasmosis is endemic.

Entities:  

Mesh:

Year:  2001        PMID: 11283812     DOI: 10.1086/319756

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras.

Authors:  Vincent Peigne; Françoise Dromer; Caroline Elie; Olivier Lidove; Olivier Lortholary
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

2.  Histoplasmosis infections worldwide: thinking outside of the Ohio River valley.

Authors:  Nathan C Bahr; Spinello Antinori; L Joseph Wheat; George A Sarosi
Journal:  Curr Trop Med Rep       Date:  2015-06-01

3.  High Mortality and Coinfection in a Prospective Cohort of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients with Histoplasmosis in Guatemala.

Authors:  Blanca Samayoa; Monika Roy; Angela Ahlquist Cleveland; Narda Medina; Dalia Lau-Bonilla; Christina M Scheel; Beatriz L Gomez; Tom Chiller; Eduardo Arathoon
Journal:  Am J Trop Med Hyg       Date:  2017-07       Impact factor: 2.345

4.  Histoplasmosis in HIV-Infected Patients: Epidemiological, Clinical and Necropsy Data from a Brazilian Teaching Hospital.

Authors:  Alessandro Henrique Damasceno-Escoura; Delio José Mora; Anderson Clayton Cardeal; Júlio Cesar Berto-Nascimento; Renata Margarida Etchebehere; Antônio Carlos Oliveira de Meneses; Sheila Jorge Adad; Adilha Misson Rua Micheletti; Mario León Silva-Vergara
Journal:  Mycopathologia       Date:  2020-02-20       Impact factor: 2.574

5.  Clinical and Laboratory Profile of Persons Living with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome and Histoplasmosis from a Colombian Hospital.

Authors:  Diego H Caceres; Angela M Tobón; Angela Ahlquist Cleveland; Christina M Scheel; Dedsy Y Berbesi; Jesús Ochoa; Angela Restrepo; Mary E Brandt; Tom Chiller; Beatriz L Gómez
Journal:  Am J Trop Med Hyg       Date:  2016-08-01       Impact factor: 2.345

6.  Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin.

Authors:  David van Duin; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

7.  Diagnostic value of culture and serological tests in the diagnosis of histoplasmosis in HIV and non-HIV Colombian patients.

Authors:  Karen Arango-Bustamante; Angela Restrepo; Luz Elena Cano; Catalina de Bedout; Angela Maria Tobón; Angel González
Journal:  Am J Trop Med Hyg       Date:  2013-09-16       Impact factor: 2.345

8.  Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum.

Authors:  Joshua D Nosanchuk; Judith N Steenbergen; Li Shi; George S Deepe; Arturo Casadevall
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

9.  A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages.

Authors:  Li Shi; Priscila C Albuquerque; Eszter Lazar-Molnar; Xintao Wang; Laura Santambrogio; Attila Gácser; Joshua D Nosanchuk
Journal:  Eukaryot Cell       Date:  2008-05-16

10.  Two specific strains of Histoplasma capsulatum causing mucocutaneous manifestations of histoplasmosis: preliminary analysis of a frequent manifestation of histoplasmosis in southern Brazil.

Authors:  Luciano Z Goldani; Valério R Aquino; Luciano W Lunardi; Vanessa S Cunha; Rodrigo P Santos
Journal:  Mycopathologia       Date:  2008-12-27       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.